CTOs on the Move

LTZ Therapeutics

www.ltztherapeutics.com

 
LTZ Therapeutics is an immunotherapy-focused biotech company to develop novel therapies to improve clinical outcomes in patients with cancer and other diseases with an unmet clinical need.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

LTZ Therapeutics raised $17M on 04/07/2022

Similar Companies

Roka Bioscience

Roka Bioscience is a Warren, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IgGenix

IgGenix is an early-stage, venture backed biotechnology company founded on breakthrough advances in Steve Quake`s laboratory at Stanford in collaboration with allergy clinician and researcher Kari Nadeau.

Tides Medical

Tides Medical is a privately funded medical technology firm located in Lafayette, LA, is a leader in the growing market for amniotic membrane technology. Our focus is on providing patients with safe, effective therapies, physicians with reliable produc...

Flame Biosciences

Flame Biosciences is a clinical stage company focused on the research, development and commercialization of transformative therapies for cancer and other inflammatory conditions.

Vericel

Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is a third generation autologous cellularized scaffold product that is indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing 1 additional cell product. Ixmyelocel-T is a multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). Developing autologous (patient`s own) cell therapies—with integrity Vericel uses rigorous scientific methods to develop novel therapies for the treatment of patients with autologous (patient`s own) cells. In addition, personal integrity, team work, collaboration, and innovative technology are the foundations of our work. We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us.